Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) saw a large decrease in short interest in the month of November. As of November 30th, there was short interest totalling 32,020,860 shares, a decrease of 21.7% from the November 15th total of 40,895,453 shares. Approximately 9.4% of the company’s shares are sold short. Based on an average daily volume of 14,347,869 shares, the days-to-cover ratio is currently 2.2 days.

Valeant Pharmaceuticals Intl (NYSE VRX) opened at $20.89 on Thursday. The company has a debt-to-equity ratio of 4.84, a current ratio of 1.26 and a quick ratio of 1.03. The company has a market cap of $7,270.00, a PE ratio of 3.45, a price-to-earnings-growth ratio of 0.58 and a beta of -0.22. Valeant Pharmaceuticals Intl has a one year low of $8.31 and a one year high of $22.81.

VRX has been the topic of a number of recent analyst reports. Cantor Fitzgerald reissued a “buy” rating and issued a $23.00 price objective on shares of Valeant Pharmaceuticals Intl in a research report on Tuesday, August 29th. ValuEngine raised shares of Valeant Pharmaceuticals Intl from a “hold” rating to a “buy” rating in a research report on Monday, October 2nd. TD Securities raised shares of Valeant Pharmaceuticals Intl from a “hold” rating to a “buy” rating and set a $20.00 price objective on the stock in a research report on Friday, November 3rd. Vetr lowered shares of Valeant Pharmaceuticals Intl from a “strong-buy” rating to a “buy” rating and set a $19.18 price objective on the stock. in a research report on Monday, December 4th. Finally, TheStreet raised shares of Valeant Pharmaceuticals Intl from a “d” rating to a “c-” rating in a research report on Tuesday, November 7th. Six analysts have rated the stock with a sell rating, ten have assigned a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Valeant Pharmaceuticals Intl currently has an average rating of “Hold” and an average target price of $17.72.

In other news, Director John Paulson acquired 344,216 shares of Valeant Pharmaceuticals Intl stock in a transaction that occurred on Thursday, November 16th. The shares were bought at an average cost of $14.40 per share, with a total value of $4,956,710.40. Following the transaction, the director now directly owns 94,559 shares of the company’s stock, valued at approximately $1,361,649.60. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 5.87% of the company’s stock.

Hedge funds have recently modified their holdings of the business. Paulson & CO. Inc. boosted its stake in shares of Valeant Pharmaceuticals Intl by 12.5% during the second quarter. Paulson & CO. Inc. now owns 21,813,400 shares of the specialty pharmaceutical company’s stock valued at $377,372,000 after purchasing an additional 2,428,900 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Valeant Pharmaceuticals Intl by 4.2% during the second quarter. Vanguard Group Inc. now owns 7,274,717 shares of the specialty pharmaceutical company’s stock valued at $125,853,000 after purchasing an additional 294,643 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Valeant Pharmaceuticals Intl by 327.6% during the third quarter. Dimensional Fund Advisors LP now owns 4,472,185 shares of the specialty pharmaceutical company’s stock valued at $64,086,000 after purchasing an additional 3,426,410 shares in the last quarter. CIBC World Markets Inc. boosted its stake in shares of Valeant Pharmaceuticals Intl by 2.3% during the second quarter. CIBC World Markets Inc. now owns 3,741,413 shares of the specialty pharmaceutical company’s stock valued at $64,726,000 after purchasing an additional 83,592 shares in the last quarter. Finally, Chou Associates Management Inc. boosted its stake in shares of Valeant Pharmaceuticals Intl by 29.7% during the second quarter. Chou Associates Management Inc. now owns 3,053,843 shares of the specialty pharmaceutical company’s stock valued at $53,030,000 after purchasing an additional 700,000 shares in the last quarter. Institutional investors and hedge funds own 49.45% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Valeant Pharmaceuticals Intl Inc (VRX) Short Interest Down 21.7% in November” was originally reported by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this piece of content can be viewed at https://www.watchlistnews.com/valeant-pharmaceuticals-intl-inc-vrx-short-interest-down-21-7-in-november/1775371.html.

Valeant Pharmaceuticals Intl Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Receive News & Ratings for Valeant Pharmaceuticals Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl and related companies with MarketBeat.com's FREE daily email newsletter.